ReviewClinical rheumatology2025
Etanercept-induced sarcoidosis presenting with bilateral panuveitis: diagnostic value of ocular signs and therapeutic response to IL-17A inhibition-a case-based review.
Review in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Emerging therapeutic targets in non-infectious uveitis and scleritis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor necrosis factor-alpha (TNF-α) inhibitors are effective treatments for autoimmune diseases but may cause paradoxical adverse events (PAEs), including sarcoid-like granulomatosis. Etanercept, a soluble TNF receptor fusion protein, has been more frequently associated with this phenomenon compared to monoclonal antibodies. CASE PRESENTATION: We describe a 61-year-old man with chronic plaque psoriasis on long-term etanercept therapy who developed bilateral visual symptoms. Ophthalmologic evaluation revealed granulomatous panuveitis with retinal vasculitis and macular edema. Imaging and lung biopsy confirmed pulmonary sarcoidosis with non-caseating granulomas. Etanercept was discontinued, and systemic corticosteroids were started. Because of steroid dependence, secukinumab (an IL-17A inhibitor) was introduced, together with an intravitreal dexamethasone implant for refractory macular edema. Over a 4-year follow-up, the patient achieved complete and sustained resolution of ocular inflammation with stable systemic control, without the need for further corticosteroids. DISCUSSION: This case illustrates a rare but clinically significant presentation of etanercept-induced sarcoidosis with primary ocular involvement. Unlike typical psoriatic uveitis, the bilateral granulomatous pattern prompted further systemic work-up, which revealed otherwise silent pulmonary disease. To our knowledge, this is the first long-term report of etanercept-induced ocular sarcoidosis successfully managed with secukinumab, which allowed steroid withdrawal. While IL-17A inhibitors are not yet approved for uveitis, available data and our observation suggest a potential role in selected cases.
conclusionEtanercept-induced ocular sarcoidosis is a rare but clinically significant PAE. Prompt recognition and multidisciplinary management are crucial to prevent vision loss. IL-17A inhibition may represent a promising steroid-sparing therapeutic option when TNF-α inhibitors are contraindicated or cause paradoxical reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.